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Abstract 
Background 
The present study aimed to examine the relationship between tumour invasiveness (T stage), 
the local and systemic environment and cancer specific survival (CSS) of patients with 
primary operable colorectal cancer. 
Methods 
The tumour microenvironment was examined using measures of the inflammatory infiltrate 
(Klintrup-Makinen (KM) grade and Immunoscore), tumour stroma percentage (TSP) and 
tumour budding.  The systemic inflammatory environment was examined using modified 
Glasgow Prognostic Score (mGPS) and neutrophil:lymphocyte ratio (NLR).  5-year CSS was 
examined. 
Results 
331 patients were included.  Increasing T stage was associated with colonic primary, N stage, 
poor differentiation, margin involvement and venous invasion (P<0.05).  T stage was 
significantly associated with KM grade (P=0.001), Immunoscore (P=0.016), TSP (P=0.006), 
tumour budding (P<0.001), and elevated mGPS and NLR (both P<0.05). 
In patients with T3 cancer, N stage stratified survival from 88% to 64%, whereas 
Immunoscore and budding stratified survival from 100% to 70% and from 91% to 56% 
respectively.  The Glasgow Microenvironment Score, a score based on KM grade and TSP, 
stratified survival from 93% to 58%. 
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Conclusion 
Although associated with increasing T stage, local and systemic tumour environment 
characteristics, and in particular Immunoscore, budding, TSP and mGPS, are stage-
independent determinants of survival and may be utilised in the staging of patients with 
primary operable colorectal cancer. 
Key words: Colorectal cancer, tumour microenvironment, inflammation, prognosis, staging 
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Introduction  
The staging of patients with colorectal cancer is based on the Tumour, Node, 
Metastasis (TNM) classification as described by the Union for International Cancer Control/ 
American Joint Committee on Cancer (UICC/ AJCC).  For patients without metastatic 
disease, prognosis is primarily determined by the depth of invasion of the primary tumour (T 
stage) as well as the presence of regional lymph node metastases (N stage).  However, the use 
of TNM-based staging remains problematical, since increasing disease stage does not 
necessarily reflect a stepwise increase in risk of recurrence or death.  For example, the 
survival of patients with Stage IIIa (T1/2, N1) colon cancer is superior to that of patients with 
stage IIb (T4, N0) disease (O'Connell et al, 2004). 
Given that TNM criteria are suboptimal, there is increasing effort to refine colorectal 
cancer staging.  One potential approach is to examine the molecular characteristics of the 
tumour, and various approaches ranging from assessment of gene expression profiles to more 
comprehensive molecular subtyping have been described (Guinney et al, 2015; Salazar et al, 
2011).  These have largely failed to translate from use as clinical research tools, with the 
practicalities of assays employed, differing methodologies, and high costs prohibiting routine 
clinical use (Church et al, 2012; Munro et al, 2005).  Additionally, except for assessment of 
KRAS status and microsatellite instability (De Roock et al, 2010; Guastadisegni et al, 2010), 
the clinical utility of such characteristics as predictive markers of treatment response remain 
largely unknown. 
A differing approach is assessment of the local and systemic tumour environment, 
encompassing the interface between tumour and host (Hanahan & Weinberg, 2011; 
McAllister & Weinberg, 2014).  Loss of local anti-tumour immune responses (Bindea et al, 
2013; Klintrup et al, 2005; Pages et al, 2009), expansion of the tumour-associated stroma 
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(Huijbers et al, 2013; Mesker et al, 2007), and the presence of tumour budding (Ueno et al, 
2002), have all been identified as markers of poor prognosis.  Such characteristics may be 
readily assessed utilising routinely available formalin-fixed paraffin embedded specimens 
and pathological techniques, and have been validated as stage independent predictors of 
survival.  Similarly, the presence of an elevated systemic inflammatory response, as 
evidenced not only by circulating cytokines (Kantola et al, 2012), but also routinely 
measured inflammatory mediators (McMillan, 2013), is similarly associated with poorer 
survival. 
We have previously reported that combined assessment of the tumour inflammatory 
cell infiltrate (utilising both generalised inflammatory cell infiltrate and CD3+ and CD8+ T-
lymphocyte subsets) and the tumour-associated stroma (using tumour stroma percentage 
(TSP)), hold independent and complimentary prognostic value in patients with colorectal 
cancer (Park et al, 2015a; Park et al, 2015b).  Furthermore, the addition of tumour budding 
further stratifies survival independent of these two characteristics (van Wyk et al, 2016).  As 
such, assessment of these measures, in addition to the systemic inflammatory response, 
provides the opportunity to utilise characteristics of both the tumour and the host to determine 
prognosis. 
Although the presence of adverse local and systemic characteristics has been 
previously reported to be associated with increasing T stage, it is of interest that they retain 
independent prognostic value (Pages et al, 2005; Park et al, 2015b; Park et al, 2016b; van 
Wyk et al, 2016).  Therefore, given the routine reporting of T stage, it would be of interest to 
examine their prognostic value relative to present TNM-based staging.  As such, the aim of 
the present study was to examine the interrelationships between T stage, components of the 
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local and systemic environment, and survival of patients undergoing potentially curative 
resection of primary operable colorectal cancer. 
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Patients and Methods 
Patients were identified from a prospectively maintained database of colorectal cancer 
resections in a single surgical unit in Glasgow Royal Infirmary.  For the present study, 
patients who on the basis of pre-operative computed tomography and intra-operative findings 
were considered to have undergone potentially curative, elective resection of stage I-III 
colorectal adenocarcinoma between January 1997 and May 2008 were included.  Exclusion 
criteria included emergency, localised or palliative resection, pre-operative 
chemoradiotherapy and death within 30 days of operation.  Study approval was granted by 
the West of Scotland Research Ethics Committee. 
Patients were staged according to the 5th edition of TNM criteria as is current practice 
in the United Kingdom (Loughrey et al, 2014).  Tumours were categorised as either proximal 
(caecum, ascending colon, hepatic flexure and transverse colon), distal (splenic flexure, 
descending colon, sigmoid) or rectal (rectosigmoid and rectum) on the basis of operative and 
pathological reports.  The presence of venous invasion was identified routinely using routine 
elastica staining.   
Patients were followed up for a minimum of five years.  Patients were discussed 
following surgery at multi-disciplinary meetings comprised of clinicians with a specialist 
interest in colorectal cancer, where those with stage III and high-risk stage II disease were 
considered for adjuvant, 5-fluoruracil-based chemotherapy according to contemporary 
treatment protocols.  Cause and date of death were crosschecked with the cancer registration 
system and Registrar General (Scotland), with records complete until 31st March 2014 which 
acted as the censor date.  Cancer-specific survival was measured from date of surgery until 
date of death from recurrent or metastatic colorectal cancer, and overall survival was 
measured until date of death from any cause. 
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Assessment of mismatch repair status 
Mismatch repair (MMR) status was performed for a subgroup of patients who had 
tissue included in a tissue microarray (TMA) as previously described (Park et al, 2016a).  
Briefly, TMA sections were stained for MLH1, MSH6, MSH2 and PMS2.  In accordance 
with UK NEQAS (Arends et al, 2008), tumours were considered MMR competent if tumour 
epithelial nuclear staining was positive, and MMR deficient if tumour epithelial staining was 
negative with positive staining of intratumoural lymphocytes. 
Assessment of the tumour microenvironment 
The generalised inflammatory cell infiltrate was examined using the Klintrup-
Mäkinen (K-M) grade as previously described (Klintrup et al, 2005).  Briefly, using H&E-
stained sections of the deepest point of tumour invasion, the density of the generalised 
inflammatory cell infiltrate was graded as low-grade (no increase or mild, patchy increase in 
inflammatory cells) or high-grade (prominent inflammatory reaction, forming a band at the 
invasive margin, or florid cup-like infiltrate at the invasive edge with frequent destruction of 
cancer cell islands).  The adaptive, T-lymphocytic infiltrate was examined as previously 
described (Richards et al, 2014).  Briefly, full sections of the deepest point of invasion were 
stained for mature (CD3+) and cytotoxic (CD8+) T-lymphocytes and the density of each cell 
type within intraepithelial compartment and invasive margin semi-quantitatively graded as 
either high or low.  The Immunoscore, a quantitative assessment of CD3+ and CD8+ density 
in both regions, has previously been reported utilising automated digital pathology (Galon et 
al, 2014).  Manual semi-quantitative assessment has been shown to correlate strongly with 
automated assessment, whilst allowing for increased discrimination of non-specific 
background staining (De Smedt et al, 2015).  As such, a semi-quantitative Immunoscore was 
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utilised, calculated from the number of compartments with a high density of immune cells, 
ranging from Im0 (all regions low density) to Im4 (all regions high density).  On the basis of 
previous work, patients were stratified into three prognostic groups: Im0/1 (low density), Im 
2/3 (moderate density) and Im4 (high density) (Park et al, 2015a). 
Tumour stroma percentage (TSP), tumour necrosis, and tumour budding were all 
examined using H&E-stained sections of the invasive margin as previously described 
(Mesker et al, 2007; Pollheimer et al, 2010; van Wyk et al, 2016).  Briefly, excluding 
necrosis and mucin deposits, TSP was calculated as low (<50% of tumour area) or high 
(>50% of tumour area).  Tumour necrosis was graded as low (absent or <10% of tumour 
area) or high (>10% of tumour area).  To assess tumour budding, the number of tumour buds 
(tumour cells with up to five nuclei or single tumour cells) in 10 high-power fields was 
counted.  On the basis of previous work, a budding count greater than 20 was considered 
high-grade (van Wyk et al, 2016). 
Assessment of the systemic inflammatory response 
Pre-operative serum C-reactive protein (CRP), albumin and differential white cell 
count were measured within 30 days prior to surgery as routine and recorded prospectively.  
The systemic inflammatory response was measured using the modified Glasgow Prognostic 
Score (mGPS) and neutrophil:lymphocyte ratio (NLR) as previously described (Guthrie et al, 
2013; McMillan, 2013).  Patients with CRP 10mg/l were given a score of 0, patients with 
CRP>10mg/l a score of 1, and patients with CRP>10mg/L and albumin <35g/L a score of 2.  
On the basis of previous literature review, NLR>5 was considered elevated (Guthrie et al, 
2013). 
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Statistical Analysis 
The relationship between T stage and characteristics of the local and systemic 
environments was examined using the 2-test for linear trend. Their relationship and cancer-
specific and overall survival was examined using Kaplan-Meier log-rank analysis to 
calculated five-year survival (standard error (SE)).  Variables associated with survival were 
entered into a Cox proportional hazards regression analysis, using a backwards-conditional 
method.  A p-value0.05 was considered statistically significant.  All statistical analyses were 
performed using SPSS version 22.0 (IBM SPSS, IL, USA). 
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Results 
A total of 331 patients were included.  Two thirds of patients were 65 or older at time 
of surgery and 52% were male.  Thirty percent of patients underwent resection of rectal 
cancer.  Eighty-two patients received adjuvant therapy.  The majority of patients (90%) had a 
tumour breaching through muscularis propria, with 208 and 90 patients with T3 and T4 
tumours respectively.  Of the remaining patients, eight had a T1 tumour and 25 had a T2 
tumour.   
The relationship between T stage and clinicopathological characteristics is displayed 
in Table 1. T stage was associated with colonic primary (P<0.001), N stage (P<0.01), margin 
involvement, venous invasion (both P<0.001), and poor differentiation (P<0.05).  In addition, 
T stage was associated with adjuvant chemotherapy (P<0.05) but not age or sex.  Mismatch 
repair status was available for 209 patients, and was not associated with increasing T stage. 
The relationship between T stage and the local and systemic environment was 
examined (Table 2). T stage was associated with high-grade necrosis, infiltrative invasive 
margin, high-grade tumour budding, low K-M grade (all P0.001) and high TSP (P<0.01).  
Furthermore, increasing T stage was associated with lower Immunoscore and elevated 
systemic inflammatory responses as measured by mGPS and NLR (all P<0.05).  Certain 
characteristics appeared to become more prevalent earlier than others;  there was a 
statistically significant increase in the number of patients with high grade necrosis and low K-
M grade observed in the shift from T2 to T3 (Bonferroni-corrected P<0.05), whereas the 
proportion of patients with an infiltrative margin, high grade budding and high TSP showed a 
statistically greater increase between T3 to T4 (P<0.05).  Although an elevated mGPS and 
NLR showed a greater stepwise increase between T3 to T4, this did not reach statistical 
significance. 
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The relationship between tumour site, T stage and the local and systemic environment 
was examined (Supplementary Table 1).  In patients with cancer of the right colon, increasing 
T stage was associated with tumour budding and TSP (both P<0.01) and showed a trend 
towards an association with necrosis (P=0.054) and an infiltrative margin (P=0.081).  In 
patients with cancer of the left colon, increasing T stage was associated with necrosis 
(P<0.01), an infiltrative margin (P<0.05) and tumour budding (P<0.001).  In patients with 
rectal cancer, increasing T stage was associated with an infiltrative margin, weak KM grade 
(both P0.001) and showed a trend towards weak Immunoscore (P=0.096). 
The relationship between the local and systemic tumour environment and five-year 
survival was examined (Table 3).  The median follow-up of survivors was 134 months 
(interquartile range 108-170 months) with 96 cancer deaths and 105 non-cancer deaths.  Five-
year cancer-specific survival of the whole cohort was 77%.  N stage, character of margin, 
budding, K-M grade, TSP, Immunoscore and mGPS all stratified five-year cancer-specific 
survival (all P<0.001), whereas tumour necrosis, the NLR and MMR status did not.  On 
multivariate analysis (Table 4), controlling for age, adjuvant chemotherapy, T stage and 
venous invasion, tumour budding, Immunoscore and mGPS remained independently 
associated with survival whereas N stage, character of margin and K-M grade did not; TSP 
showed a non-significant association with survival (HR 1.64, P=0.084). 
Five-year overall survival was 65% (Table 3).  N stage, necrosis, budding, K-M 
grade, TSP, Immunoscore and mGPS (all P<0.05), but not MMR status, character of margin 
or NLR stratified five-year overall survival.  On multivariate analysis (Table 4), controlling 
for age, adjuvant therapy, T stage and venous invasion, tumour budding, TSP and mGPS 
remained independently associated with survival, whereas N stage, necrosis and K-M grade 
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did not; Immunoscore showed a non-significant association with improved survival (HR 
0.77, P=0.053). 
As tumour budding, TSP, Immunoscore and mGPS appeared to be consistently 
associated with both cancer-specific and overall survival, the relationship between these 
characteristics, tumour site and survival was examined (Table 5).  Tumour budding and 
mGPS were associated with both cancer-specific and overall survival across all tumour sites.  
Tumour stroma percentage showed an association with cancer-specific across all tumour 
sites, but only appeared to stratify overall survival of patients with right and left colonic 
cancer but not rectal cancer.  Immunoscore was associated with cancer-specific and overall 
survival of patients with right-sided and rectal cancers; although appearing to stratify cancer-
specific and overall survival of patients with left colonic cancers, this did not reach statistical 
significance. 
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Discussion 
The results of the present study confirm the relationship between tumour invasion and 
the presence of adverse characteristics within the local and systemic environment.  Such 
characteristics, namely tumour budding, TSP, Immunoscore and the mGPS, appeared to have 
greater prognostic value than evaluation of N stage in patients with primary operable 
colorectal cancer. 
Advancing T stage correlated significantly with the presence of an increasingly 
tumour-supportive microenvironment as evidenced by loss of host immune responses, 
expansion of the tumour-associated stroma and the presence of tumour budding.  This is 
consistent with previous work, whereby such adverse characteristics become more prevalent 
with increasing tumour size and depth of invasion (Bindea et al, 2013; Park et al, 2015b; 
Vayrynen et al, 2016).  It was of interest however, that the progression of each of these 
characteristics appeared to occur in a stepwise manner, with the proportion of some appearing 
to increase at an earlier T stage than others.  For example, attenuation of the generalised local 
inflammatory cell infiltrate appeared to occur at a relatively early stage (between T2 and T3), 
whereas the presence of tumour budding and increasing TSP appeared to occur later, with a 
clear stepwise change evident between T3 and T4 tumours.  
Although based on observational data, the present results potentially inform our 
understanding of the nature of the tumour microenvironment and its development in patients 
with colorectal cancer.  Loss of adaptive, anti-tumour immune responses, or ‘immune escape’ 
may be the initial precipitant allowing sustained tumour growth and invasion (Mlecnik et al, 
2011), with other adverse tumour microenvironment characteristics developing further 
downstream in the presence of “pro-tumour” local and systemic immune responses 
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(McAllister & Weinberg, 2014).  Certainly, it is recognised that the immune 
microenvironment evolves in tandem with stage progression, favouring the development of a 
more pro-tumour “immunome” as T stage increases (Bindea et al, 2013).  As this progresses 
and anti-tumour immunity is degraded, it may allow the development of further pro-tumour 
microenvironment characteristics, such as recruitment and activation of tumour-associated 
fibroblasts (Chrysanthopoulou et al, 2014), and budding (Koelzer et al, 2015). 
Subgroup analysis found that the relationship between T stage and local and systemic 
environment characteristics was not consistent across tumour sites.  In patients with right-
sided tumours, increasing T stage was associated with increasing TSP but not loss of the 
inflammatory cell infiltrate; conversely, the opposite was found in patients with rectal cancer.  
This may reflect the molecular heterogeneity of tumour arising from different sites 
(Birkenkamp-Demtroder et al, 2005), with tumour microenvironment characteristics, such as 
necrosis, mesenchymal and inflammatory cell infiltration being associated with distinct 
molecular characteristics (Guinney et al, 2015; Vayrynen et al, 2016).  Consistent with this, 
in the present study MMR deficiency was identified in 30% of right-sided cancers compared 
to only 6% of rectal cancers (P<0.001). 
Subsequent revisions of the TNM staging system have introduced significant changes 
to pathological definitions, particularly with respect to nodal stage and often with little 
supporting evidence (Quirke et al, 2007).  Such changes have led to concern regarding the 
potential “upstaging of patients” (Nagtegaal et al, 2011; Ueno et al, 2012).  Given that the 
criteria for T stage remains relatively standardised and largely unchanged since first 
described by Dukes (Dukes, 1932), it presents an attractive and logical foundation to base 
disease staging upon.  It has previously been proposed that staging should be weighted more 
towards T stage, with less reliance on the presence of nodal involvement as a defining factor 
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for high-risk disease (Gunderson et al, 2010; Li et al, 2016).  However, although associated 
with increasing T stage, when controlling for T stage, N stage and venous invasion, 
assessment of local and systemic environment characteristics were independently associated 
with survival.  Indeed, such characteristics may further stratify T stage in terms of survival. 
For example, the presence of budding, an expanded stroma and loss of the local immune 
response may identify patients with T1/2 tumours with poorer survival.  If this were proven to 
be the case then such characteristics may aid, for example, in the decision between 
polypectomy rather than formal segmental resection in patients with polyp cancers. 
In addition to MMR status, numerous other molecular characteristics have been 
confirmed to hold prognostic value in patients with colorectal cancer (Guinney et al, 2015; 
Sinicrope et al, 2015).  However, these are not uniformly employed in routine clinical 
practice and remain costly.  Therefore, it was of interest that assessment of the local and 
systemic environment was of greater prognostic value than MMR status.  Furthermore, 
prognostic utility appeared consistent across different tumour sites, suggesting that molecular 
heterogeneity may not confound the present results.  This further supports results of previous 
studies, whereby assessment of local and systemic inflammatory profiles, tumour-associated 
stroma and tumour budding have been shown to hold prognostic value independent of both 
MMR status (Huijbers et al, 2013; Park et al, 2016a; Rozek et al, 2016), and more extensive 
molecular characterisation (Ogino et al, 2009).  Indeed, the relatively simple methodologies 
employed in the present study, and their reliance on routine pathological specimens, would 
make them attractive candidates for widespread clinical use. 
The relatively small number of patients with T1/2 disease limits the present study.  
Indeed, validation in a larger cohort, encompassing patient with earlier stage disease is 
warranted.  Furthermore, it was not possible to examine the predictive value of local and 
systemic environment characteristics with respect to the use of adjuvant chemotherapy.  
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Whether the tumour and host factors examined in the present study may be utilised in such a 
manner would be of considerable interest. In conclusion, the local and systemic environment, 
although associated with increasing T stage, have independent prognostic value.  In 
particular, the Immunoscore, tumour budding, TSP and the mGPS may be effectively 
employed in the staging of patients with primary operable colorectal cancer.
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Table 1. The relationship between T stage and clinicopathological characteristics of patients 
undergoing elective, primary resection of stage I-III colorectal cancer.  
 
  T1 T2 T3 T4  
 N=8 
(%) 
N=25 
(%) 
N=208 
(%) 
N=90 
(%) 
P 
Host characteristics      
Age  
<65 
65-74 
>75 
 
1 (13) 
5 (62) 
2 (25) 
 
9 (36) 
8 (32) 
8 (32) 
 
69 (33) 
70 (34) 
69 (33) 
 
33 (37) 
27 (30) 
30 (33) 
0.713 
Sex  
Female 
Male 
 
5 (62) 
3 (38) 
 
16 (64) 
9 (36) 
 
93 (45) 
115 (55) 
 
46 (51) 
44 (49) 
0.533 
Adjuvant 
therapy (330) 
 
No 
Yes 
 
6 (75) 
2 (25) 
 
23 (92) 
2 (8) 
 
159 (76) 
49 (24) 
 
60 (67) 
29 (33) 
0.030 
Tumour characteristics      
Tumour site  
Right colon 
Left colon 
Rectum 
 
0 (0) 
2 (25) 
6 (75) 
 
7 (28) 
5 (20) 
13 (52) 
 
78 (38) 
67 (32) 
63 (30) 
 
47 (52) 
26 (29) 
17 (19) 
<0.001 
N stage  
0 
1 
2 
 
5 (62) 
3 (38) 
0 (0) 
 
20 (80) 
4 (16) 
1 (4) 
 
139 (67) 
56 (27) 
13 (6) 
 
45 (50) 
32 (36) 
13 (14) 
0.002 
Tumour 
differentiation 
 
Well/ mod 
Poor 
 
7 (87) 
1 (13) 
 
24 (96) 
1 (4) 
 
189 (91) 
19 (9) 
 
72 (80) 
18 (20) 
0.016 
Margin 
involvement 
 
Absent 
Present 
 
8 (100) 
0 (0) 
 
25 (100) 
0 (0) 
 
205 (99) 
3 (1) 
 
72 (80) 
18 (20) 
<0.001 
Venous invasion  
Absent 
Present 
 
8 (100) 
0 (0) 
 
23 (92) 
2 (8) 
 
140 (67) 
68 (33) 
 
45 (50) 
45 (50) 
<0.001 
Mismatch 
repair status 
(209) 
 
Competent 
Deficient 
 
7 (87) 
1 (13) 
 
15 (88) 
2 (12) 
 
110 (87) 
17 (13) 
 
44 (77) 
13 (23) 
0.161 
(n) denotes number of cases when patients missing
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Table 2. The relationship between T stage, the tumour microenvironment and systemic 
environment of patients undergoing elective, primary resection of stage I-III colorectal 
cancer. 
 
 T1 (%) T2 (%) T3 (%) T4 (%)  
Tumour microenvironment N=8 (%) N=25 (%) N=208 (%) N=90 (%) P 
Necrosis (297)  
Absent 
Present 
 
7 (87) 
1 (13) 
 
19 (90) 
2 (10) 
 
106 (56) 
82 (44) 
 
37 (46) 
43 (54) 
<0.001 
Invasive margin 
(312) 
 
Expansile 
Infiltrative 
 
7 (87) 
1 (13) 
 
18 (82) 
4 (18) 
 
119 (60) 
78 (40) 
 
34 (40) 
51 (60) 
<0.001 
Tumour budding 
(302) 
 
Low 
High 
 
5 (71) 
2 (29) 
 
18 (78) 
5 (22) 
 
146 (74) 
50 (26) 
 
33 (43) 
43 (57) 
<0.001 
Klintrup-
Mäkinen grade 
(307) 
 
Strong 
Weak 
 
5 (62) 
3 (38) 
 
14 (67) 
7 (33) 
 
63 (32) 
133 (68) 
 
21 (26) 
61 (74) 
0.001 
Tumour stroma 
percentage (331) 
 
Low 
High 
 
7 (87) 
1 (13) 
 
19 (76) 
6 (24) 
 
168 (81) 
40 (19) 
 
56 (62) 
34 (38) 
0.006 
Immunoscore 
(226) 
 
0-1 
2-3 
4 
 
2 (29) 
2 (29) 
3 (42) 
 
8 (42) 
7 (37) 
4 (21) 
 
68 (49) 
54 (39) 
17 (12) 
 
37 (61) 
17 (28) 
7 (12) 
0.016 
Systemic environment      
mGPS (330)  
0 
1 
2 
 
6 (75) 
2 (25) 
0 (0) 
 
16 (64) 
8 (32) 
1 (4) 
 
127 (61) 
51 (25) 
30 (14) 
 
45 (51) 
29 (33) 
15 (17) 
0.031 
NLR (225)  
≤5 
>5 
 
6 (86) 
1 (14) 
 
17 (85) 
3 (15) 
 
115 (82) 
25 (18) 
 
39 (67) 
19 (33) 
0.033 
(n) denotes number included when patients missing. mGPS – modified Glasgow Prognostic 
Score, NLR – neutrophil:lymphocyte ratio 
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Table 3. The relationship between tumour, microenvironment and systemic environment 
characteristics of patients undergoing elective, primary resection of stage I-III colorectal 
cancer and five-year cancer-specific and overall survival. 
 
 
 5-yr CSS % 
(SE) 
P  5-yr OS % 
(SE) 
P 
All   77 (2) -  65 (3) - 
N stage  
N0 
N1 
N2 
  
86 (2) 
64 (5) 
46 (10) 
<0.001 
 
  
74 (3) 
56 (5) 
33 (9) 
0.011 
Mismatch repair status  
Deficient 
Competent 
  
88 (6) 
73 (3) 
0.100   
79 (7) 
62 (4) 
0.551 
Necrosis  
Absent 
Present 
  
80 (3) 
72 (4) 
0.130   
75 (3) 
53 (4) 
0.001 
Margin  
Expansile 
Infiltrative 
  
82 (3) 
69 (4) 
<0.001   
69 (3) 
60 (4) 
0.269 
Tumour budding  
Low 
High 
  
90 (2) 
54 (5) 
<0.001   
75 (3) 
49 (5) 
<0.001 
Klintrup-Mäkinen grade  
Strong 
Weak 
  
90 (3) 
70 (3) 
<0.001   
78 (4) 
59 (3) 
0.004 
Tumour stroma percentage  
Low 
High 
  
81 (3) 
64 (6) 
<0.001   
69 (3) 
53 (6) 
0.015 
Immunoscore  
4 
2-3 
0-1 
  
96 (3) 
87 (4) 
62 (5) 
<0.001   
84 (7) 
75 (5) 
51 (5) 
<0.001 
Modified Glasgow Prognostic 
Score 
 
0 
1 
2 
  
83 (3) 
72 (5) 
57 (8) 
<0.001   
75 (3) 
57 (5) 
39 (7) 
<0.001 
Neutrophil: Lymphocyte Ratio  
≤5 
>5 
  
79 (3) 
73 (7) 
0.362   
70 (3) 
56 (7) 
0.080 
CSS – cancer-specific survival, OS – overall survival
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Table 4. The relationship between N stage, the tumour microenvironment and systemic 
environment and cancer-specific and overall survival of patients undergoing elective, primary 
resection of stage I-III colorectal cancer. 
 
 Multivariate survival analysis (HR, 95%CI) 
Characteristic Cancer-specific 
survival 
P Overall survival P 
N stage (0/ 1/ 2) 1.04 (0.71-1.52) 0.836 1.10 (0.83-1.47) 0.509 
Necrosis (Absent/ 
present) 
- - 1.40 (0.97-2.02) 0.074 
Margin (Expansile/ 
infiltrative) 
1.29 (0.73-2.27) 0.388 - - 
Budding (Absent/ 
present) 
2.80 (1.58-4.94) <0.001 1.56 (1.07-2.27) 0.021 
Klintrup-Mäkinen 
grade (Strong/ 
weak) 
1.18 (0.58-2.41) 0.650 1.20 (0.78-1.83) 0.406 
Tumour stroma 
percentage (Low/ 
high) 
1.64 (0.94-2.88) 0.084 1.89 (1.25-2.84) 0.002 
Immunoscore (0-1/ 
2-3/ 4) 
0.41 (0.25-0.67) <0.001 0.77 (0.59-1.00) 0.053 
mGPS (0/ 1/ 2) 1.55 (1.08-2.23) 0.017 1.46 (1.14-1.88) 0.003 
 
mGPS- modified Glasgow Prognostic Score. Multivariate analysis performed controlling for 
age, tumour site, adjuvant therapy use, T stage and venous invasion. 
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Table 5. The relationship between local and systemic environment characteristics, tumour site, and five-year cancer-specific and overall survival 
of patients undergoing elective, primary resection of stage I-III colorectal cancer. 
 
 5-year cancer-specific survival (SE)  5-year overall survival (SE) 
 Right P  Left P  Rectal P  Right P  Left P  Rectal P 
Tumour budding  
Low 
High 
 
91 (3) 
50 (8) 
<0.001   
90 (4) 
68 (9) 
0.001   
91 (4) 
43 (10) 
<0.001   
76 (5) 
47 (8) 
0.010   
74 (6) 
66 (9) 
0.052   
74 (6) 
36 (9) 
0.005 
Tumour stroma percentage  
Low 
High 
 
80 (4) 
60 (9) 
0.029   
82 (4) 
67 (10) 
0.037   
78 (5) 
66 (9) 
0.063   
73 (4) 
47 (9) 
0.026   
70 (5) 
57 (10) 
0.133   
63 (6) 
57 (9) 
0.617 
Immunoscore  
4 
2-3 
0-1 
 
100 (0) 
83 (8) 
61 (7) 
0.003   
87 (12) 
85 (7) 
67 (9) 
0.191   
100 (0) 
92 (5) 
58 (9) 
0.002   
92 (7) 
76 (9) 
50 (7) 
0.046   
75 (15) 
71 (9) 
61 (9) 
0.289   
80 (13) 
78 (8) 
45 (8) 
0.005 
Modified Glasgow Prognostic Score  
0 
1 
2 
 
83 (5) 
81 (6) 
48 (11) 
0.001   
85 (5) 
60 (10) 
86 (13) 
0.061   
81 (5) 
68 (11) 
53 (15) 
0.052   
79 (5) 
67 (7) 
35 (9) 
0.001   
79 (5) 
43 (9) 
50 (18) 
<0.001   
68 (6) 
55 (11) 
42 (14) 
0.115 
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Supplementary Table 1. The relationship between tumour site, T stage, the tumour 
microenvironment and systemic environment of patients undergoing elective, primary 
resection of stage I-III colorectal cancer. 
 
Right colon N=132 T1  T2 T3 T3  
Tumour microenvironment N=0 N=7 N=78 N=47 P 
Necrosis (119)  
Absent 
Present 
 
- 
- 
 
4 
0 
 
42 
30 
 
20 
23 
0.054 
Invasive margin 
(121) 
 
Expansile 
Infiltrative 
 
- 
- 
 
4 
1 
 
44 
28 
 
 
21 
23 
0.081 
Tumour budding 
(123) 
 
Low 
High 
 
- 
- 
 
6 
0 
 
53 
21 
 
21 
22 
0.002 
Klintrup-
Mäkinen grade 
(120) 
 
Strong 
Weak 
 
- 
- 
 
1 
3 
 
24 
48 
 
12 
32 
0.625 
Tumour stroma 
percentage (132) 
 
Low 
High 
 
- 
- 
 
7 
0 
 
66 
12 
 
29 
18 
0.001 
Immunoscore (84)  
0-1 
2-3 
4 
 
- 
- 
- 
 
2 
0 
2 
 
25 
15 
8 
 
19 
10 
3 
0.194 
Systemic environment      
mGPS (132)  
0 
1 
2 
 
- 
- 
- 
 
5 
1 
1 
 
39 
24 
15 
 
22 
15 
10 
0.415 
NLR (89)  
≤5 
>5 
 
- 
- 
 
3 
1 
 
42 
11 
 
21 
11 
0.229 
mGPS – modified Glasgow Prognostic Score, NLR – neutrophil:lymphocyte ratio  
29 
Left colon N=100 T1  T2 T3 T3  
Tumour microenvironment N=2 N=5 N=67 N=26 P 
Necrosis (93)  
Absent 
Present 
 
2 
0 
 
5 
0 
 
34 
28 
 
9 
15 
0.006 
Invasive margin 
(99) 
 
Expansile 
Infiltrative 
 
1 
1 
 
4 
1 
 
42 
25 
 
8 
17 
0.020 
Tumour budding 
(90) 
 
Low 
High 
 
2 
0 
 
4 
1 
 
50 
12 
 
5 
16 
<0.001 
Klintrup-
Mäkinen grade 
(98) 
 
Strong 
Weak 
 
1 
1 
 
3 
2 
 
25 
42 
 
8 
16 
0.354 
Tumour stroma 
percentage (100) 
 
Low 
High 
 
2 
0 
 
3 
2 
 
55 
12 
 
17 
9 
0.224 
Immunoscore (67)  
0-1 
2-3 
4 
 
1 
1 
0 
 
1 
1 
1 
 
18 
21 
6 
 
11 
5 
1 
0.196 
Systemic environment      
mGPS (99)  
0 
1 
2 
 
2 
0 
0 
 
2 
3 
0 
 
46 
15 
6 
 
13 
10 
2 
0.309 
NLR (59)  
≤5 
>5 
 
1 
1 
 
5 
0 
 
33 
5 
 
10 
4 
0.555 
mGPS – modified Glasgow Prognostic Score, NLR – neutrophil:lymphocyte ratio 
 
  
30 
Rectum N=99 T1  T2 T3 T3  
Tumour microenvironment N=6 N=13 N=63 N=17 P 
Necrosis (85)  
Absent 
Present 
 
5 
1 
 
10 
2 
 
30 
24 
 
8 
5 
0.126 
Invasive margin 
(92) 
 
Expansile 
Infiltrative 
 
6 
0 
 
10 
2 
 
33 
25 
 
5 
11 
0.001 
Tumour budding 
(89) 
 
Low 
High 
 
3 
2 
 
8 
4 
 
43 
17 
 
7 
5 
0.962 
Klintrup-
Mäkinen grade 
(89) 
 
Strong 
Weak 
 
4 
2 
 
10 
2 
 
14 
43 
 
1 
13 
<0.001 
Tumour stroma 
percentage (99) 
 
Low 
High 
 
5 
1 
 
9 
4 
 
47 
16 
 
10 
7 
0.324 
Immunoscore (75)  
0-1 
2-3 
4 
 
1 
1 
3 
 
5 
6 
1 
 
25 
18 
3 
 
7 
2 
3 
0.096 
Systemic environment      
mGPS (99)  
0 
1 
2 
 
4 
2 
0 
 
9 
4 
0 
 
42 
12 
9 
 
10 
4 
3 
0.266 
NLR (77)  
≤5 
>5 
 
5 
0 
 
9 
2 
 
40 
9 
 
8 
4 
0.146 
mGPS – modified Glasgow Prognostic Score, NLR – neutrophil:lymphocyte ratio 
 
 
